Taken together, our findings highlight that the CDK7/9 inhibitor SNS-032 is a promising therapeutic agent, and warrants a clinical trial for its efficacy in ESCC patients, even those with metastasis. This evidence concerns the gene CDK7 and esophageal squamous cell carcinoma.